Article | August 13, 2017

Avoid the Do-Over: Why Early Investment in a Scalable Manufacturing Process is Critical

Source: Thermo Fisher Scientific

By Enrico Corona, Director, Pharmaceutics & Process Technology, and Jonathan Sutch

Avoid the Do-Over: Why Early Investment in a Scalable Manufacturing Process is Critical

The road to take a drug compound from discovery to commercialization is long, expensive and often fraught with unforeseen challenges. While every project will undoubtedly face some bumps along its path, far too many programs hit insurmountable obstacles that require innovators to backtrack and correct their course before proceeding, further extending timelines and adding costs.